August 30, 2024Open Access

Efficacy, safety, and prognostic modeling in neoadjuvant immunotherapy for esophageal squamous cell carcinoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

To evaluate the safety and efficacy of neoadjuvant immunotherapy in patients with esophageal squamous cell carcinoma (ESCC) and construct a prognostic model.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Song et al. (Fri,) studied this question.

synapsesocial.com/papers/68e5a2c4b6db64358753d4e9 https://doi.org/https://doi.org/10.1016/j.intimp.2024.112845

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Evaluation of Optimal Threshold of Neutrophil-Lymphocyte Ratio and Its Association With Survival Outcomes Among Patients With Head and Neck Cancer2022 · 60 citations
2A tutorial on calibration measurements and calibration models for clinical prediction models2020 · 443 citations
3Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma2020 · 48 citations
4Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK2019 · 8 citations
5World Medical Association Declaration of Helsinki2013 · 29,167 citations

Me gusta

Guardar

Ver artículo completo